Investor ATP Life Science Ventures, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by ATP Life Science Ventures, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2022-01-21 13G/A KDNY / Chinook Therapeutics Inc 4,028,937 0
2021-06-29 13D/A STOK / Stoke Therapeutics, Inc. 17,206,045 1,912,256
2021-06-29 13D/A AKRO / Akero Therapeutics, Inc. 5,415,203 674,640
2020-11-27 13D/A STOK / Stoke Therapeutics, Inc. 16,786,713 17,206,045
2020-11-16 13G KDNY / Chinook Therapeutics Inc 4,028,937
2020-07-14 13D/A TTNP / Titan Pharmaceuticals, Inc. 5,838,869
2019-07-01 13D STOK / Stoke Therapeutics, Inc. 16,786,713 16,786,713
2019-07-01 13D AKRO / Akero Therapeutics, Inc. 5,415,203 5,415,203
2019-06-29 13D STOK / Stoke Therapeutics, Inc. 16,786,713
2019-06-29 13D AKRO / Akero Therapeutics, Inc. 5,415,203
2016-06-28 13D/A TTNP / Titan Pharmaceuticals, Inc. 1,069,220
2016-06-03 13D/A TTNP / Titan Pharmaceuticals, Inc. 1,069,220 1,069,220
2016-06-02 13D/A TTNP / Titan Pharmaceuticals, Inc. 1,754,546 1,069,220
2016-02-12 13D/A DERM / Journey Medical Corporation
2016-02-12 13G AVTX / Avalo Therapeutics, Inc. 595,436
2016-02-12 13D/A TTNP / Titan Pharmaceuticals, Inc. 1,754,546
2014-10-17 13D DERM / Journey Medical Corporation 1,258,637